Jm. Frazao et al., INTERMITTENT ORAL 1-ALPHA-HYDROXYVITAMIN D2 IS EFFECTIVE AND SAFE FORTHE SUPPRESSION OF SECONDARY HYPERPARATHYROIDISM IN HEMODIALYSIS-PATIENTS, Nephrology, dialysis, transplantation, 13, 1998, pp. 68-72
Calcitriol and alfacalcidol are useful in suppressing parathyroid horm
one (PTH) in haemodialysis patients, but hypercalcaemia and hyperphosp
hataemia are frequent, The vitamin D analogue, 1 alpha-hydroxyvitamin
D-2 (1 alpha D-2), has a higher therapeutic index in animal models. Pr
eviously, 1 alpha D-2, 4 mu g/day or 4 mu g/haemodialysis, lowered iPT
H to the target range in 87.5% of 24 haemodialysis patients with moder
ate to severe secondary hyperparathyroidism (plasma iPTH, 359-1521 pg/
ml). The incidences of hypercalcaemia (serum Ca > 2.8 mM) or hyperphos
phataemia (serum P > 2.23 mM) were low. Later, 10 of these patients we
re re-treated with 1 alpha D-2, initial dose, 10 mu g, thrice weekly w
ith haemodialysis. The iPTH was suppressed as readily, and there was n
o greater incidence of hypercalcaemia and hyperphosphataemia. Based on
these data, a large, multicentre study is ongoing in California and T
ennessee/Mississippi, using 1 alpha D-2 in haemodialysis patients with
iPTH > 400 pg/ml. In this and the earlier studies, only calcium-based
phosphate binders were used to control serum phosphorus. The initial
dose, 10 mu g thrice weekly with haemodialysis, is adjusted to maintai
n a target iPTH within the range of 150 300 mu g/ml; the final dose ra
nge is 2.5-20 mu g per haemodialysis. The protocol includes 8 weeks of
wash-out with no vitamin D, 16 weeks of open label treatment period w
ith 1 alpha D-2, and finally 8 weeks of randomized double blinded trea
tment with either continued 1 alpha D-2 or placebo. Forty two patients
from California and 38 from Tennessee/Mississippi have completed 16 w
eeks of open label treatment. In California, iPTH declined from 832 +/
- 95 pg/ml at baseline to 222 +/- 71 pg/ml at the nadir and to 477 +/-
117 pg/ml at week 16 of the treatment. In Tennessee/Mississippi, the
iPTH declined from 977 +/- 65 pg/ml to 286 +/- 42 pg/ml at the lowest
point and to 493 +/- 79 at the end of the treatment. Plasma iPTH reach
ed or fell below the target range in 84% of the 80 patients completing
open treatment. Asymptomatic hypercalcaemia (serum Ca > 2.8 mM) incre
ased episodes/100 weeks during wash-out to 3.6 episodes/100 treated we
eks in California and from 0 to 3.7 episodes in Tennessee/Mississippi.
In California and Tennessee, the episodes of hyperphosphataemia (seru
m P > 2.2 mM) increased from 5.0 and 5.0 epiodes per 100 patient/week
during wash-out to 10.1 and 10.9 episodes/100 treatment weeks, respect
ively, with 1 alpha D-2 treatment. There were no adverse events in ass
ociation with 1 alpha D-2 treatment. Thus, oral 1 alpha D-2 is safe an
d highly effective for the treatment of secondary hyperparathyroidism.